Novo Holdings A/S
CIK 1388325 · last filed 2026-05-06
Novo Holdings A/S is a corporate insider who has filed 152 SEC Form 4 insider transactions across 44 companies since 2007. The most recent filing, for COAG, was dated May 6, 2026. Across all open-market trades the lifetime net is −$157.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.49B across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.49B
Companies
44
Total Filings
152
Lifetime Open-Market Net
-$157.03M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| COAG | 10%+ Owner | 4,180,550 | $47.26 | $197.57M | $0 | 1 | 2026-05-06 |
| AVLN | 10%+ Owner | 3,327,734 | $27.79 | $92.48M | $10.00M | 1 | 2026-05-05 |
| MPLT | 10%+ Owner | 2,733,681 | $12.31 | $33.65M | $16.20M | 1 | 2025-10-30 |
| IO Biotech, Inc. (IOBT) Delisted | 10%+ Owner | 4,354,449 | $0.05 | $209.0K | $7.66M | 5 | 2024-07-26 |
| SPRB | 10%+ Owner | 34,000 | $41.60 | $1.41M | $738.2K | 6 | 2024-03-25 |
| MGX | 10%+ Owner | 100,000 | $1.21 | $121.0K | $13.03M | 1 | 2024-02-15 |
| Cyteir Therapeutics, Inc. (CYT) Delisted | 10%+ Owner | 3,522,136 | $3.02 | $10.64M | $1.24M | 9 | 2023-07-20 |
| IRON | 10%+ Owner | 1,090,772 | $74.65 | $81.43M | -$57.62M | 1 | 2023-06-28 |
| OnKure Therapeutics, Inc. (RPHM) Delisted | 10%+ Owner | 333,034 | $18.20 | $6.06M | $9.29M | 2 | 2023-06-23 |
| EWTX | 10%+ Owner | 6,071,703 | $40.35 | $244.99M | $15.00M | 2 | 2022-09-16 |
| BOLT | 10%+ Owner | 185,200 | $4.02 | $744.5K | $6.40M | 2 | 2022-07-15 |
| Checkmate Pharmaceuticals, Inc. (CMPI) Delisted | 10%+ Owner | 2,162,290 | $10.50 | $22.70M | $7.48M | 2 | 2022-02-25 |
| Arcellx, Inc. (ACLX) Delisted | 10%+ Owner | 3,183,545 | $115.07 | $366.33M | $12.50M | 1 | 2022-02-09 |
| MINERVA SURGICAL INC (UTRS) Delisted | 10%+ Owner | 44,224 | $0.00 | $4 | $6.96M | 1 | 2021-10-27 |
| Verve Therapeutics, Inc. (VERV) Delisted | 10%+ Owner | 793,265 | $11.13 | $8.83M | $6.65M | 1 | 2021-06-22 |
| INGN | 10%+ Owner | 2,079,320 | $6.42 | $13.35M | -$129.87M | 5 | 2021-06-03 |
| GRTX | 10%+ Owner | 12,295 | $17.60 | $216.4K | -$4.24M | 3 | 2021-02-19 |
| Inozyme Pharma, Inc. (INZY) Delisted | 10%+ Owner | 2,194,379 | $4.00 | $8.78M | -$1.88M | 2 | 2021-02-01 |
| Damora Therapeutics, Inc. (GLTO) Delisted | 10%+ Owner | 86,578 | $28.69 | $2.48M | $5.00M | 1 | 2020-11-04 |
| Eargo, Inc. (EAR) Delisted | 10%+ Owner | 44,354 | $2.57 | $114.0K | $2.70M | 1 | 2020-10-22 |
| ALGS | 10%+ Owner | 96,583 | $4.25 | $410.5K | $3.00M | 1 | 2020-10-22 |
| PRAX | 10%+ Owner | 162,805 | $295.81 | $48.16M | $0 | 1 | 2020-10-21 |
| HRMY | 10%+ Owner | 3,754,973 | $35.77 | $134.32M | $3.18M | 2 | 2020-09-04 |
| NKTX | 10%+ Owner | 2,793,865 | $2.22 | $6.20M | $10.00M | 1 | 2020-07-16 |
| CRVS | 10%+ Owner | 1,389,498 | $13.31 | $18.49M | $6.67M | 6 | 2020-07-09 |
| MIST | 10%+ Owner | 2,434,470 | $1.07 | $2.60M | $1.16M | 2 | 2019-11-27 |
| MIRM | 10%+ Owner | 1,870,147 | $112.23 | $209.89M | $8.62M | 1 | 2019-07-23 |
| Morphic Holding, Inc. (MORF) Delisted | 10%+ Owner | 1,978,779 | $56.99 | $112.77M | $10.00M | 1 | 2019-07-01 |
| Entasis Therapeutics Holdings Inc. (ETTX) Delisted | 10%+ Owner | 1,092,008 | $2.19 | $2.39M | $16.35M | 1 | 2018-10-01 |
| KalVista Pharmaceuticals, Inc. (KALV) Delisted | 10%+ Owner | 1,726,481 | $27.00 | $46.61M | -$28.82M | 3 | 2017-10-12 |
| HTG MOLECULAR DIAGNOSTICS, INC (HTGM) Delisted | 10%+ Owner | 6,126 | $0.48 | $2.9K | $2.86M | 3 | 2017-08-25 |
| ANAB | 10%+ Owner | 1,936,604 | $52.11 | $100.92M | -$22.57M | 5 | 2017-08-21 |
| Apollo Endosurgery, Inc. (APEN) Delisted | 10%+ Owner | 1,301,842 | $10.00 | $13.02M | -$936.5K | 2 | 2017-07-26 |
| REATA PHARMACEUTICALS INC (RETA) Delisted | 10%+ Owner | 642,405 | $172.36 | $110.72M | -$1.53M | 6 | 2017-06-23 |
| IVERIC bio, Inc. (OPHT) Delisted | 10%+ Owner | 0 | — | — | -$163.30M | 6 | 2016-12-16 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | 10%+ Owner | 924,970 | — | — | $3.20M | 1 | 2016-11-02 |
| IRTC | 10%+ Owner | 2,124,448 | $117.37 | $249.35M | $1.70M | 1 | 2016-10-26 |
| CoLucid Pharmaceuticals, Inc. (CLCD) Delisted | 10%+ Owner | 3,156,563 | — | — | $15.00M | 2 | 2016-09-13 |
| Tobira Therapeutics, Inc. (TBRA) Delisted | 10%+ Owner | 1,905,789 | — | — | $755.7K | 7 | 2016-07-13 |
| FLXN | 10%+ Owner | 2,247,431 | $24.65 | $55.39M | $14.41M | 3 | 2015-06-22 |
| NEVRO CORP (NVRO) Delisted | 10%+ Owner | 2,194,841 | $5.84 | $12.82M | $3.87M | 1 | 2014-11-13 |
| OTONOMY, INC. (OTIC) Delisted | 10%+ Owner | 2,175,025 | $0.08 | $167.5K | $2.99M | 2 | 2014-08-21 |
| AKBA | 10%+ Owner | 1,516,387 | $1.27 | $1.93M | $3.10M | 1 | 2014-03-26 |
| BIOMIMETIC THERAPEUTICS, INC. (BMTI) Delisted | 10%+ Owner | 4,720,065 | — | — | $26.02M | 33 | 2010-07-19 |
Recent Filings
152 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-06 | COAG | Conv (C) | +4,180,550 | $0 | EDGAR |
| 2026-05-05 | AVLN | Mixed | +3,883,289 | $10.00M | EDGAR |
| 2025-10-30 | MPLT | Mixed | +3,686,622 | $16.20M | EDGAR |
| 2024-09-11 | IO Biotech, Inc. (IOBT) Delisted | Notice (144) | −1,000,000 | -$844.0K | EDGAR |
| 2024-07-26 | IO Biotech, Inc. (IOBT) Delisted | Sell (S) | −75,000 | -$99.1K | EDGAR |
| 2024-07-25 | IO Biotech, Inc. (IOBT) Delisted | Notice (144) | −75,000 | -$101.2K | EDGAR |
| 2024-05-14 | IO Biotech, Inc. (IOBT) Delisted | Sell (S) | −658,809 | -$802.5K | EDGAR |
| 2024-05-10 | IO Biotech, Inc. (IOBT) Delisted | Notice (144) | −658,809 | -$988.2K | EDGAR |
| 2024-03-25 | SPRB | Sell (S) | −465,021 | -$351.0K | EDGAR |
| 2024-03-20 | SPRB | Sell (S) | −1,794,999 | -$1.36M | EDGAR |
Showing 1–10 of 152
Page 1 of 16
Next
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.